LINCOCIN LINCOMYCIN 500MG 16CAPS

Product Description

1. Lincomycin has been shown to be effective in treating the following infections caused by susceptible strains of gram positive aerobes such as streptococci, pneumococci and staphylococci, or by susceptible anaerobic bacteria. 2. Infections of the upper respiratory tract including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as an adjunct in the treatment of diphtheria. Its effectiveness in treating mastoiditis can be anticipated. 3. Lower respiratory tract infections including acute bronchitis, chronic bronchitis, and pneumonia. 4. Skin and soft tissue infections including cellulitis, boils, abscesses, impetigo, acne, and wound infections. Conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis, and cutaneous gangrene should respond appropriately if they are caused by microorganisms susceptible to lincomycin therapy. 5. Bone and joint infections including osteomyelitis and septic arthritis. 6. Septicemia and endocarditis. Select cases of septicemia and / or endocarditis caused by susceptible organisms have responded well to lincomycin therapy. However, in these infections the use of bactericidal drugs is often preferred. 7. Bacillary dysentery. Although Shigella is resistant to Lincomycin in vitro (MIC of approximately 200-400 μg / mL), lincomycin has been effective in its treatment due to the very high levels of Lincomycin achieved in the intestine (approximately 3000-7000 μg / mL of feces).